ArticleTherapeutics and clinical risk management2008
Pharmacotherapeutics of epilepsy: use of lamotrigine and expectations for lamotrigine extended release.
Article in Therapeutics and clinical risk management, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 39 citations in OpenAlex.
- Factors that influence the pharmacokinetics of lamotrigine in Japanese patients with epilepsy.European journal of clinical pharmacology · 2016Trial
- Steady-state pharmacokinetics and bioavailability of immediate-release and extended-release formulations of lamotrigine in elderly epilepsy patients: Use of stable isotope methodology.Journal of clinical pharmacology · 2015Trial
- Once-daily USL255 as adjunctive treatment of partial-onset seizures: randomized phase III study.Epilepsia · 2014Trial
- USL255 extended-release topiramate: dose-proportional pharmacokinetics and tolerability in healthy volunteers.Epilepsia · 2014Trial
- A Case of Toxic Epidermal Necrolysis Caused by Lamotrigine Combined With Valproic Acid and Literature Review.Cureus · 2023Article
- Effect of Lamotrigine on Ouabain-Induced Arrhythmia in Isolated Atria of Guinea Pigs.Medical journal of the Islamic Republic of Iran · 2021Article
- Risk-Based Bioequivalence Recommendations for Antiepileptic Drugs.Current neurology and neuroscience reports · 2017Review
- The Impact of Anti-Epileptic Drugs on Growth and Bone Metabolism.International journal of molecular sciences · 2016Review
- Long-term tolerability and safety of lamotrigine extended-release: pooled analysis of three clinical trials.Clinical drug investigation · 2013Article
- Predicting pharmacokinetic stability by multiple oral administration of atypical antipsychotics.Innovations in clinical neuroscience · 2013Article
- Review of therapeutic options for adjuvant treatment of focal seizures in epilepsy: focus on lacosamide.CNS drugs · 2011Review
- Adjunctive therapy for the treatment of primary generalized tonic-clonic seizures: focus on once-daily lamotrigine.Drug design, development and therapy · 2010Review
- Efficacy, safety, and potential of extended-release lamotrigine in the treatment of epileptic patients.Neuropsychiatric disease and treatment · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The goal in managing patients with epilepsy is complete seizure freedom. Pharmacotherapeutic management of epilepsy is complicated by multiple syndromes, inter-individual differences in drug sensitivities, inter-individual differences in drug disposition, and drug interactions. Most anti-epileptic drugs (AEDs) have a therapeutic window with only a 2- to 3-fold concentration range. Extended release formulations offer advantages over their immediate release counter parts with less fluctuation in the serum concentration vs time curve and improved compliance. However, missed doses are more likely to result in prolonged "sub-therapeutic serum concentrations". Best clinical outcome may sometimes require twice daily dosing of extended release formulations even though approved for once daily dosing, as this optimally balances pharmacokinetics against compliance. Lamotrigine (LTG) is a broad spectrum AED with efficacy in partial and generalized epilepsy syndromes and good tolerability. Its metabolism is affected by co-medications which may be inducing, neutral or inhibiting of hepatic glucuronidation. Furthermore, though the average half-life in monotherapy is about 24 hours, there is a large inter-individual variation that may, including the extremes, approach a range of 10-fold. LTG-XR is expected to decrease fluctuation of serum concentration in the presence of hepatic inducing or neutral drugs. However, optimal clinical benefit in some patients may require twice daily dosing when metabolism is rapid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.